Search results for "Venous thromboembolism"
Higher risk for DVT, PE, bleeding seen after COVID-19; long-term risk for VTE recurrence may be low
A Swedish study found that patients who had COVID-19 were at higher risk for a first deep venous thrombosis (DVT) for up to three months, pulmonary embolism (PE) for up to six months, and bleeding for up to two months, while a single-center study from France found that risk for venous thromboembolism (VTE) recurrence up to a year after COVID-19 was low.
https://immattersacp.org/weekly/archives/2022/04/12/2.htm
12 Apr 2022
Managing DOACs in primary care
Primary care physicians play a crucial role in ongoing anticoagulation management, including educating patients about the signs of venous thromboembolism.
https://immattersacp.org/archives/2022/04/managing-doacs-in-primary-care.htm
1 Apr 2022
New guidelines aim to improve diverticulitis treatment
This issue includes stories on managing diverticulitis, using direct oral anticoagulants, and payment and performance measures.
https://immattersacp.org/archives/2022/04/new-guidelines-aim-to-improve-diverticulitis-treatment.htm
1 Apr 2022
New resource offers pearls for perioperative medicine
A recent book addresses perioperative medicine, including how to be a perioperative consultant, prophylaxis for venous thromboembolism, coexisting medical problems, and common postoperative complications.
https://immattersacp.org/archives/2022/02/new-resource-offers-pearls-for-perioperative-medicine.htm
1 Feb 2022
Patients presenting with acute pulmonary embolism in primary care settings can be safely managed without hospitalization, a study finds
Of more than 600 encounters involving pulmonary embolism diagnosis in primary care, patients were sent home in 20.6%, and in 37.8% of encounters referred to the ED, patients were discharged home without events. Only one outpatient had an adverse event within 30 days.
https://immattersacp.org/weekly/archives/2022/01/18/4.htm
18 Jan 2022
Apixaban shows superior effectiveness, safety compared to rivaroxaban
For patients with venous thromboembolism, initiation of apixaban was associated with lower rates of recurrence and intracranial and gastrointestinal bleeding than rivaroxaban in a population-based cohort study.
https://immattersacp.org/weekly/archives/2021/12/07/2.htm
7 Dec 2021
DOACs may be safe, effective for VTE prevention in patients with higher weight, BMI
Patients with first-time venous thromboembolism (VTE) who weighed 120 kg or more and had a body mass index (BMI) of 40 kg/m2 or more were not at higher risk for bleeding or recurrent VTE with direct-acting oral anticoagulants (DOACs) versus warfarin.
https://immattersacp.org/weekly/archives/2021/11/09/4.htm
9 Nov 2021
Long-term anticoagulation after first unprovoked VTE associated with considerable bleeding risk
Results from a systematic review and meta-analysis provide a framework for clinicians and patients to balance the benefits and harms of extended anticoagulation for unprovoked venous thromboembolism (VTE).
https://immattersacp.org/weekly/archives/2021/09/14/4.htm
14 Sep 2021
New data on delta variant of COVID-19 and vaccines
Recent research found that the risk of myocarditis and both arterial and venous clots is higher with COVID-19 infection than with vaccine administration. Other studies show that the COVID-19 delta variant has been associated with reduced mRNA vaccine effectiveness (from 91% to 66%) and an overall increased severity of illness.
https://immattersacp.org/weekly/archives/2021/08/31/1.htm
31 Aug 2021
COVID-19 research focused on anticoagulation, vaccine-induced thrombocytopenia
Two new studies support prophylactic, rather than therapeutic, anticoagulation for COVID-19 patients, and case reports provide more information about vaccine-induced immune thrombotic thrombocytopenia.
https://immattersacp.org/weekly/archives/2021/06/15/1.htm
15 Jun 2021